State-of-the-Art Reviews

The importance of a World Health Organization international pharmacovigilance database (VigiBase): novel methods for safety monitoring and surveillance of medical products

Chanyang Min[*]

[1]Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Seoul, Republic of Korea

Abstract

Pharmacovigilance and medical product safety issues are important for all global citizens. Previous studies have analyzed the disaster caused by thalidomide in 1961. In 1963, the 16th World Health Assembly was determined to create the World Health Organization (WHO) Pilot Research Project for International Drug Monitoring in order to develop and understand adverse effects of medical products. In 1968, this pilot research project developed into the WHO Programme for International drug Monitoring (earlier versions of VigiBase) coordinated by the Uppsala Monitoring Center (Uppsala, Sweden) which expanded in scale to include 153 member countries, 22 associates, and many regional reporting centers as of March 2022. The main goal of the WHO Global ICSR Database System (VigiBase) is detecting, understanding, assessing, and preventing adverse effects of medical products (herbals, complementary medicines, biologic products, blood products, medical devices, and vaccines). This article aims to provide appropriate and strong reference of adverse reactions in specific drugs and novel method to identify specific features of adverse drug reactions through data and information achieved by VigiBase.

Keywords: World Health Organization; pharmacovigilance; VigiBase; individual case safety reports.

1. Introduction

Pharmacovigilance and medical product safety issues are important for all global citizens. Previous studies have analyzed the disaster caused by thalidomide in 1961 which exposed pregnancy mothers to thalidomide and leaded many thousands of infants with congenitally malformation.[1] In 1963, the 16th World Health Assembly was determined to create the World Health Organization (WHO) Pilot Research Project for International Drug Monitoring to develop and understand adverse effects of medical products.[2] In 1968, this pilot research project developed into the WHO Programme for International drug Monitoring (VigiBase) coordinated by the Uppsala Monitoring Center (Uppsala, Sweden) and expanded into an organization with 153 member countries, 22 associates, and many regional reporting centers, as of March 2022.[3]

The main goal of VigiBase is detection, understanding, assessment, and prevention of adverse effects of medical products (herbals, complementary medicines, biologic products, blood products, medical devices, and vaccines). Adverse drug reactions are calculated and examined the individual case safety reports (ICSRs) in the WHO international pharmacovigilance database (Fig. 1).[4]

The WHO Programme for International Drug Monitoring

Fig. 1. Full and associated members of the WHO Programme for international drug monitoring.

2. Full members of the WHO programme for international drug monitoring (year they joined)

Afghanistan (2016), Albania (2020), Algeria (2021), Andorra (2008), Angola (2013), Argentina (1994), Armenia (2001), Australia (1968), Austria (1991), Azerbaijan (2018), Bangladesh (2014), Barbados (2008), Belarus (2006), Belgium (1977), Benin (2011), Bhutan (2014), Bolivia (Plurinational State of) (2013), Bosnia and Herzegovina (2019), Botswana (2009), Brazil (2001), Brunei Darussalam (2005), Bulgaria (1975), Burkina Faso (2010), Burundi (2022), Cabo Verde (2012), Cambodia (2012), Cameroon (2010), Canada (1968), Central African Republic (2022), Chad (2018), Chile (1996), China (1998), Colombia (2004), Congo (2021), Costa Rica (1991), Côte d'Ivoire (2010), Croatia (1992), Cuba (1994), Cyprus (2000), Czechia (1992), Democratic Republic of the Congo (2010), Denmark (1971), Dominican Republic (2020), Ecuador (2017), Egypt (2001), El Salvador (2017), Eritrea (2012), Estonia (1998), Eswatini (2015), Ethiopia (2008), Fiji (1999), Finland (1974), France (1986), Gambia (2021), Georgia (2018), Germany (1968), Ghana (2001), Greece (1990), Guatemala (2002), Guinea (2013), Guinea-Bissau (2022), Honduras (2020), Hungary (1990), Iceland (1990), India (1998), Indonesia (1990), Iran (Islamic Republic of) (1998), Iraq (2010), Ireland (1968), Israel (1973), Italy (1975), Jamaica (2012), Japan (1972), Jordan (2002), Kazakhstan (2008), Kenya (2010), Kuwait (2021), Kyrgyzstan (2003), Lao People's Democratic Republic (2015), Latvia (2002), Lebanon (2021), Liberia (2013), Libya (2021), Lithuania (2005), Luxembourg (2020), Madagascar (2009), Malawi (2019), Malaysia (1990), Maldives (2016), Mali (2011), Malta (2004), Mauritius (2014), Mexico (1999), Mongolia (2021), Montenegro (2009), Morocco (1992), Mozambique (2005), Namibia (2008), Nepal (2006), Netherlands

(1968), New Zealand (1968), Nicaragua (2020), Niger (2012), Nigeria (2004), North Macedonia (2000), Norway (1971), Oman (1995), Pakistan (2018), Panama (2016), Papua New Guinea (2018), Paraguay (2018), Peru (2002), Philippines (1995), Poland (1972), Portugal (1993), Republic of Korea (1992), Republic of Moldova (2003), Romania (1976), Russian Federation (1998), Rwanda (2013), Saint Vincent and the Grenadines (2020), Saudi Arabia (2009), Senegal (2009), Serbia (2000), Sierra Leone (2008), Singapore (1993), Slovakia (1993), Slovenia (2010), South Africa (1992), Spain (1984), Sri Lanka (2000), Sudan (2008), Suriname (2007), Sweden (1968), Switzerland (1991), Syrian Arab Republic (2018), Thailand (1984), Togo (2007), Tunisia (1993), Türkiye (1987), Uganda (2007), Ukraine (2002), United Arab Emirates (2013), United Kingdom of Great Britain and Northern Ireland (1968), United Republic of Tanzania (1993), United States of America (1968), Uruguay (2001), Uzbekistan (2006), Venezuela (Bolivarian Republic of) (1995), Viet Nam (1999), Yemen (2022), Zambia (2010), and Zimbabwe (1998)

3. Associate members of the WHO programme for international drug monitoring

Antigua and Barbuda, Bahamas, Bahrain, Belize, Dominica, Gabon, Grenada, Guyana, Haiti, Lesotho, Mauritania, Myanmar, Qatar, Saint Kitts and Nevis, Saint Lucia, South Sudan, Tajikistan, Timor-Leste, Anguilla, British Virgin Islands, Montserrat, and Zanzibar.

4. Data source

VigiBase contains 24 million deduplicated ICSRs, some which initiate from November 14, 1967. Each ICSR consists of data reports, country of origin (Americas, Europe, Australia, Asia, and Africa), qualification of reporters (health care professional and non-health care professional), patient data (age and sex), data of drugs (indication for the drug, dosage, route of administration, and start and end dates), adverse drug reaction data reported by Medical Dictionary for Regulatory Activities (MedDRA) classification terms (onset data, end data, seriousness, and final outcome), and additional information (concurrent use of other medication).[2, 5] The MedDRA is a hierarchical terminology classified into five levels (Lowest Level Terms, Preferred Terms, High Level Terms, High Level Group Terms, and System Organ Classes).[6] According to the WHO and Uppsala Monitoring Center policy, all patient data are anonymized and publication of data on individual patients is not permitted.[2, 3, 7] Serious adverse drug reactions are defined as death, life-threatening events, hospitalization (initial or prolonged), disability (leading to persistent or clinically), and clinically serious situations judged by physician reporting the case.

5. Data limitations

VigiaBase has some limitations. First, as the data is collected from 153 member countries, 22 associates, and many regional reporting centers, the quality and diversity of the data varies depending on the reporting method of each country.[8] Certain countries report only suspected adverse drug reaction with potential causal association between drug and ICSR, while the

United States reports all ADRs, even if they are not linked to drug use.[5] Secondly, while a small proportion of reports have been generated only from clinical trials, most reports are based on multiple sources (physicians, pharmacists, health care professionals, and patients), which results high heterogeneity of the dataset.[9]

6. Signal detection

VigiBase is based on a case-non-case analysis (disproportionality analysis) in order to generate and report suspected adverse reaction signals in the entire database (Fig. 2). These analyses, with Information component (IC) value used the Bayesian neural network method developed and validated by Uppsala Monitoring Centre[1, 10], can be used to compare proportion of specific adverse reaction for selected drug with the proportion of the same adverse drug reaction for control drugs (entire database). The statistical formula is log2 ($[N_{observed}+0.5]/[N_{expected}+0.5]$, where $N_{observed}$ is the actual number of ICSRs and $N_{expected}$ is the expected number of ICSRs. $N_{expected}$ is calculated by ($N_{drug} * N_{effect})/N_{total}$, where N_{drug} is the number of ICSRs for the drug, regardless of adverse drug reaction, N_{effect} is the number of ICSRs for the adverse drug reaction, regardless of the drug, and N_{total} is the total number of ICSRs in entire database. $IC_{0.25}$ is the lower end of a 95% credibility interval and the positive value ($IC_{0.25} >0$) is considered to be the statistically significant signal detection validated by Uppsala Monitoring Center.[1] This method of using probabilistic logic in information theory was used to identify and find adverse drug reaction signals by a regulatory agency and to avoid false positive signals between a selected drug and a common signal from the entire database.

VigiBase

Variables	
Patient age	18-44 years 0-27 days
Patients sex	Female Male
Reportet type	Consumer Physician
Seriousness criteria	Hospitalization Life threatening
Drug	Spedific drug

Number of reports	18 to 44 years	Not 18 to 44 years
Europe	A	B
Rest of the world	C	D

$$\text{Disproportionality score} = \log2 \frac{A + k}{BC/D + k}$$

Fig. 2. Case-non-case analysis (disproportionality analysis) generating and reporting suspected adverse reaction signals.

7. Conclusions

The WHO Global ICSR Database System (VigiBase) provides an appropriate and strong reference of adverse reactions in specific drugs and a novel method to identify specific features of adverse drug reactions. I believe that future findings through VigiBase may contribute to a more comprehensive understanding of adverse reactions in specific drugs, improvement of public and global health, and prevention of global drug disaster such as thalidomide.

Capsule Summary

This review article aimed to provide appropriate and strong reference of adverse reactions in specific drugs and novel method to identify specific features of adverse drug reactions through data and information achieved by VigiBase.

Acknowledgements

Author Contribution

Dr CM contributed to the preparation of this review.

Funding

Conflicts of Interest

The author has no conflicts of interest to declare for this study.

Provenance and peer review

Not commissioned; externally peer reviewed.

References

1. Juhlin K, Star K, Norén GN. A method for data-driven exploration to pinpoint key features in medical data and facilitate expert review. Pharmacoepidemiology and Drug Safety. 2017;26(10):1256-65.

2. Wakao R, Taavola H, Sandberg L, Iwasa E, Soejima S, Chandler R, et al. Data-driven identification of adverse event reporting patterns for Japan in VigiBase, the WHO global database of individual case safety reports. Drug Safety. 2019;42(12):1487-98.

3. Chandler RE, Juhlin K, Fransson J, Caster O, Edwards IR, Norén GN. current safety concerns with human papillomavirus vaccine: A cluster analysis of reports in VigiBase(®). Drug Safety. 2017;40(1):81-90.

4. Jung SY, Kim MS, Li H, Lee KH, Koyanagi A, Solmi M, et al. Cardiovascular events and

safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database. Clinical and Translational Science. 2022;15(2):501-13.

5. Kim MS, Jung SY, Ahn JG, Park SJ, Shoenfeld Y, Kronbichler A, et al. Comparative safety of mRNA COVID-19 vaccines to influenza vaccines: A pharmacovigilance analysis using WHO international database. Journal of Medical Virology. 2022;94(3):1085-95.

6. Martin S, Azzouz B, Morel A, Trenque T. Anti-NMDA receptor encephalitis and vaccination: A disproportionality analysis. Frontiers in Pharmacology. 2022;13:940780.

7. Merino D, Gérard AO, Thümmler S, Ben Othman N, Viard D, Rocher F, et al. Drug-associated parosmia: New perspectives from the WHO safety database. Journal of Clinical Medicine. 2022;11(16).

8. Kim MS, Jung SY, Lee SW, Li H, Koyanagi A, Kronbichler A, et al. Hepatobiliary adverse drug reactions associated with remdesivir: The WHO international pharmacovigilance study. Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of The American Gastroenterological Association. 2021;19(9):1970-2.e3.

9. Norén GN, Meldau EL, Chandler RE. Consensus clustering for case series identification and adverse event profiles in pharmacovigilance. Artificial Intelligence in Medicine. 2021;122:102199.

10. Lee S, Yang JW, Jung SY, Kim MS, Yon DK, Lee SW, et al. Neuropsychological adverse drug reactions of Remdesivir: analysis using VigiBase, the WHO global database of individual case safety reports. European Review for Medical and Pharmacological Sciences. 2021;25(23):7390-7.